SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is trending as an "oil play" caught in a significant short squeeze, with community discussion highlighting its resilience and upward momentum despite a recent private placement and a very high cost to borrow shares amidst broader energy sector tailwinds.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant attention as NVIDIA's increased focus on photonics validates the sector, with community excitement amplified by its collaboration with Quantum Computing Inc. on 3.2Tbps optical engines. Management's recent update detailing a strong revenue ramp and engagement with even bigger partners further fuels optimism about its essential technology for scaling AI data center solutions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is dominating trending discussions amid speculation of impending positive Phase 3 REGAL trial results and a potential acquisition, fueling a strong short squeeze narrative. The stock's robust performance, hitting new 52-week highs in a challenging market, indicates significant institutional accumulation and growing conviction in its non-toxic cancer treatments.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Heightened geopolitical tensions, particularly surrounding drone warfare, are driving significant investor speculation around Red Cat Holdings as a key defense technology play. The community is actively discussing the company's potential for substantial government contracts from the Drone Dominance Program and its advanced drone systems, even amid concerns about market volatility and potential stock offerings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a strong Q4 revenue beat and robust future guidance outlining substantial revenue growth by 2027, fueling bullish sentiment around its fully funded constellation deployment and upcoming satellite launches. The community is actively discussing the company's significant progress and market strength, challenging skeptics amid news of further announcements expected this week.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB saw a sharp drop following its Q4 earnings, where strong results were overshadowed by cautious forward guidance, sparking a heated debate among investors; some view the current rebound as a prime buying opportunity given its AI relevance, while others see it as a temporary "dead cat bounce" amidst broader software sector concerns.

Foley Trasimene Acquisition Corp. II operates as a blank check company. The firm is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by William Patrick Foley II on July 15, 2020 and is headquartered in Las Vegas, NV.

Paysafe Limited

Paysafe Ltd

Paysafe (PSFE) is trending following its Q4 earnings report, which surpassed adjusted EPS expectations and provided broadly aligned 2026 guidance, igniting fierce debate among investors who point to the company's persistent debt and historical underperformance against those highlighting its undervaluation and potential for a strategic turnaround.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing a notable V-shaped rebound, with community discussion highlighting perceived market manipulation and the consistent rewarding of dip buyers, fueled by news of US efforts to secure oil flows through the Strait of Hormuz amidst escalating geopolitical tensions.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as investors rally around its stronger-than-anticipated earnings and an upbeat forecast for returning to sales growth, with widespread discussion focusing on the new CEO's strategic investments in stores and digital initiatives to fuel this turnaround.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors celebrate a new significant contract with L3Harris to build spacecraft platforms for missile tracking, bolstering its role in space defense. This news arrives amidst ongoing community speculation and anticipation regarding the impending Lunar Terrain Vehicle (LTV) contract award from NASA, with many viewing a recent stock dilution as a strategic move to fund future growth in an expanding space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Atomera’s stock offering is at a discount of 40% when compared to the closing price on Friday.</li><li>The company stated that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.</li><li>Atomera added that the stock offering is expected to close on or about Feb. 24, 2026.</li></ul>Atomera Inc. (ATOM) stock declined nearly 13% in Monday’s opening trade after the company announced the pricing of a new stock offering.Atomera announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share. This is at a discount of 40% from the stock’s closing price on Friday.<h2 class="st-heading-2">What Will Atomera Use The Funds For?</h2>Atomera stated in its announcement that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.The company added that the stock offering is expected to close on or about Feb. 24, 2026.Atomera reported its fourth-quarter (Q4) results earlier this month, posting a loss of $0.14 per share, in line with Wall Street expectations. The company reported revenue of $0.05 million, while the consensus estimate was $0.1 million, according to Stocktwits data.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ATOM">Atomera</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.Despite Atomera’s share price decline, one bullish user said it's a buying opportunity.<stembedurl>https://stocktwits.com/BioRocket/message/645608846</stembedurl>Another user stated they’re surprised by Atomera’s stock offering, noting that the company didn't need cash.<stembedurl>https://stocktwits.com/DinoMcnuggets/message/645607759</stembedurl><a href="https://stocktwits.com/symbol/ATOM">ATOM stock</a> is up 217% year-to-date and 9% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-removed-from-wedbush-best-ideas-list/cZRtp2lR4ya">Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Atomera Incorporated logo is seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Equity

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.</li><li>The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12.</li><li>Evommune said EVO301 showed a favorable safety profile with no serious adverse events reported.</li></ul>Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade before paring some of the gains to hover 50% higher in the opening trade after the company reported positive results from its atopic dermatitis trial.Evommune stated that its atopic dermatitis treatment, EVO301, met its primary endpoint at week 12 during the&nbsp;mid-stage trial. The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/EVMN">Evommune</a> trended in the ‘neutral’ territory at the time of writing. The EVMN stock was among the top five trending tickers on the platform.<h2 class="st-heading-2">Evommune Details Results Of The Trial</h2>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.“These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Evommune President and CEO, Luis Peña.The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12.Evommune said EVO301 showed a favorable safety profile, with no serious adverse events reported and no treatment-related discontinuations due to adverse events.Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, stated that EVO301’s ability to target the interleukin-18 (IL-18) mechanism and demonstrate clinically relevant activity could present patients with “real benefits.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user stated that there has been “only good news” with the Evommune stock so far.<stembedurl>https://stocktwits.com/swingingg/message/644564885</stembedurl>Another user stated that the IL-18, a known inflammatory pathway which plays a key role in various immune processes, is “working great” for dermatitis.<stembedurl>https://stocktwits.com/JanetBSmellin/message/644548490</stembedurl><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> is up 45% year-to-date and 44% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-bitcoin-volatility-bug-as-well-as-feature/cZbUI8AR4Yx">Michael Saylor Calls Bitcoin Volatility Both A Bug And A Feature, Touts It As ‘Digital Capital’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.

<ul class="summary-bullets"><li>In Kentucky, TeraWulf has acquired a former industrial site in Hawesville, which has approximately 480 MW of existing power availability.</li><li>In Maryland, where TeraWulf is headquartered, the company has acquired the Morgantown Generating Station.</li><li>This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually.</li></ul>Shares of TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) surged more than 10% during extended hours of trading on Monday after the company announced that it is expanding its digital and power infrastructure portfolio.&nbsp;The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.<h2 class="st-heading-2">Details</h2>TeraWulf said these acquisitions added about 1.5 gigawatts (GW) of capacity to its portfolio and advanced the company’s strategy of developing energy-advantaged locations with near-term power availability, long-term scalability, and the ability to support customer demand and broader grid needs.In Kentucky, TeraWulf has acquired a former industrial site in Hawesville. The site includes more than 250 buildable acres for compute capacity and offers immediate access to robust power infrastructure, the statement said.&nbsp;The Hawesville site has approximately 480 megawatts (MW) of existing power availability, with the potential to further expand over time. Development is expected to occur in phases, allowing TeraWulf to scale efficiently alongside customer demand.In Maryland, where TeraWulf is headquartered, it has acquired the Morgantown Generating Station. The acquisition establishes TeraWulf’s presence in the Pennsylvania-New Jersey-Maryland (PJM) market and reinforces the company’s strategy of reinvesting in existing energy assets to support grid reliability and long-term economic activity.<h2 class="st-heading-2">Portfolio Expansion</h2>With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.“These acquisitions reflect our strategy of reinvesting in existing energy infrastructure to support grid reliability, long-term economic activity, and responsible growth,” said Paul Prager, Chairman and Chief Executive Officer of TeraWulf.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WULF trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said that “2 additional site announcement today DOUBLES the AI/HPC capacity”.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/643740254</stembedurl>Shares in the company have jumped more than 200% over the past 12 months.&nbsp;&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Why Is TeraWulf Stock Rallying More Than 10% After Hours?

With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.

<ul class="summary-bullets"><li>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva.</li><li>Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</li><li>Last month, Immunitybio said that it recently met with the U.S. FDA to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</li></ul>Immunitybio Inc. (IBRX) said on Monday that it has launched a mid-stage clinical study in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) with no need for chemotherapy.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell">said</a> that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab, and will not require any lymphodepleting chemotherapy unlike conventional CAR-T cell therapies.<h2 class="st-heading-2">Why The Trial?</h2>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva. Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.The new mid-stage study is designed to evaluate whether further stimulation of innate and adaptive immune responses may enhance the depth and durability of anti-tumor activity, Immunitybio said, while adding that the company is hopeful for Anktiva potentially augmenting the actions of the cell therapy and Rituximab.The study will enroll patients with indolent NHL, including Waldenström’s Macroglobulinemia, who are relapsed or are refractory after at least two prior lines of therapy. Treatment will be provided without chemotherapy.<h2 class="st-heading-2">Anktiva Troubles</h2>Last month, Immunitybio said that it recently met with the U.S. Food and Drug Administration to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.The company had submitted the application in 2025 but was rejected and is now looking to resubmit it with more information. The company then said that it would submit the additional information within 30 days, and that the added information does not need a new trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX shares remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained about 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.

<ul class="summary-bullets"><li>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million.</li><li>For the current quarter (Q2), the company expects to report revenue of approximately $107 million to $108 million, marking a growth of approximately 16% percent year over year.</li><li>Twist also said that it expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.</li></ul>Shares of Twist Bioscience Corporation (TWST) jumped 8% on Monday after the company hiked its fiscal year 2026 revenue guidance on the heels of a first-quarter (Q1) earnings report that beat Wall Street estimates.<h2 class="st-heading-2">Upbeat Outlook</h2>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million, and exceeding an analyst estimate of $430.84 million, according to data from Fiscal AI. &nbsp;For the current quarter (Q2), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.twistbioscience.com/static-files/af6dbd56-d91e-429e-b337-a8e2675fc255">expects</a> to report revenue of approximately $107 million to $108 million, marking a growth of about 16% percent year over year at the midpoint, and exceeding an estimated $105.08 million.Twist also said that it expects to achieve adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven in the fourth-quarter of fiscal 2026.<h2 class="st-heading-2">Q1 Numbers</h2>For Q1, the company reported total revenue of $103.7 million, marking a growth of 17%, and above an expected $100.33 million, due to an increase in customers. The company said that it shipped products to about 2,538 customers in Q1 of fiscal 2026, versus approximately 2,376 in the same quarter of the previous fiscal year.Net loss for the quarter came in at $30.5 million, compared to $31.6 million in the corresponding quarter of fiscal 2025.The company also ended the quarter with $198 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TWST stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A user applauded the earnings as “solid” progress for investors.<stembedurl>https://www.stocktwits.com/DBRGLong/message/643661292</stembedurl><a href="https://stocktwits.com/symbol/TWST">TWST stock</a> has dropped 16% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-bond-offering-funding-ai-cloud-infrastructure/cZbgYA1R4ki">ORCL Stock In Focus As Tech Giant Reportedly Launches Bond Offering To Cover Half Of 2026 Funding Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TWST Shares Rise 8% — What’s Driving The Rally?

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 

<ul class="summary-bullets"><li>The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.</li><li>Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA.</li></ul>Shares of Protalix BioTherapeutics, Inc. (PLX) closed 13% higher on Friday after it announced that a European Medicines Agency committee has recommended approval of a new dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, in Fabry disease.The Committee for Medicinal Products for Human Use <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.protalix.com/news-releases/news-release-details/chiesi-global-rare-diseases-and-protalix-biotherapeutics-4">recommended</a> approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients. Currently approved dosing regimen requires patients to visit infusion centers every two weeks for treatment while the proposed new regimen would allow it to be stretched to every four weeks.<h2 class="st-heading-2">Turnaround</h2>The positive opinion follows CHMP’s re-examination of the company’s application for the additional dosing regimen. The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA. The agency is expected to announce a decision by March 2026.Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme, leading to harmful accumulation of fats in cells. Symptoms include severe neuropathic pain in hands/feet, skin lesions, decreased sweating, and organ damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PLX stock improved from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user appreciated that the company was persistent in getting a positive opinion. However, the stock should have rallied more on the news, they said.“But the $25 million is great news and hopefully should lessen the risk of capital raise for their gout trials. Finally, one decent obstacle out of the way,” they wrote.<stembedurl>https://www.stocktwits.com/BryGuy29/message/643515194</stembedurl><a href="https://stocktwits.com/symbol/PLX">PLX stock</a> has dropped about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/peloton-reportedly-lays-off-11-percent-workforce/cmySvT7R4Sv">Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.

<ul class="summary-bullets"><li>Attorney General's petition for review challenges PHMSA’s attempt to evade state regulation through its orders to federalize the Las Flores Pipelines.</li><li>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;</li><li>The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill.&nbsp;</li></ul>Sable Offshore shares plunged more than 14% on Friday after its two California pipeline restart came under scrutiny from a California Attorney General.&nbsp;California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.<h2 class="st-heading-2">Lawsuit Details</h2>Filed in the United States Court of Appeals for the Ninth Circuit, the Attorney General's petition for review challenges PHMSA’s alleged attempt to evade state regulation through its orders to federalize the Las Flores Pipelines, approve Sable Offshore’s restart plan, and issue Sable an emergency permit to restart oil transport through the pipelines.California Attorney General Rob Bonta, in a statement, said the administration broke the law by reclassifying the Las Flores pipelines last month as "interstate" even though they run between two California counties and are subject to state regulation.&nbsp;“In its latest unlawful power grab, the Trump Administration is illegally claiming exclusive federal authority over two of California's onshore pipelines. California has seen first-hand the devastating environmental and public health impacts of coastal oil spills — yet the Trump Administration will stop at nothing to evade state regulation which protects against these very disasters,” Bonta in a statement.&nbsp;<h2 class="st-heading-2">Sable’s Pipelines</h2>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;“PHMSA has issued an emergency special permit for segments of the interstate Santa Ynez Pipeline System (specifically segments 324 and 325), approving the Company’s implementation of enhanced integrity management practices and specifying operational conditions,” it said in a statement.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SOC trended in ‘bearish’ territory amid ‘extremely low’ message volume.&nbsp;Shares in the company have fallen 62% over the past 12 months.&nbsp; &nbsp;

A deserted oil factory in Maracaibo, Venezuela, pictured on December 27, 2019. (Photo by Humberto Matheus/NurPhoto via Getty Images)

Sable Offshore Plunged 14% Today – What Is The Feud With California State?

California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders of allowing Sable Offshore’s two pipelines to restart operations.

<ul class="summary-bullets"><li>The company said the property and equipment is located in Radersburg, Montana and was acquired for $4.75 million in cash.</li><li>The company said it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;</li></ul>Shares of United States Antimony Corporation (UAMY) rallied on Friday led by optimism among retail traders who expect the stock price to double this year.&nbsp;The stock was up more than 7% at the time of writing and was among the top trending stocks on Stocktwits.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around UAMY trended in ‘extremely bullish’ territory amid ‘high’ message volume.One bullish user said that ‘sky’s the limit for the stock’.<stembedurl>https://stocktwits.com/jayrebs71/message/642708197</stembedurl>Another user predicted the stock to hit $20.<stembedurl>https://stocktwits.com/Milodino12/message/642705651</stembedurl>Shares in the company have rallied 514% over the past 12 months.&nbsp;<h2 class="st-heading-2">Recent News</h2>United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility. The property and equipment which is located in Radersburg, Montana, between Helena and Bozeman, Montana, is fully operational, and was acquired for $4.75 million in cash, it said in a statement.The company also said that it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;The Radersburg Mill is a mineral processing facility equipped with both gravity and flotation circuits enabling the concentration of many minerals including stibnite, the primary antimony mineral. The facility has crushing and grinding circuits that reduce the ore to small particles in order to "liberate" target minerals such as gold, silver, copper, tungsten or stibnite amongst many others, the company said.&nbsp; &nbsp;

In this photo illustration, the United States Antimony (US Antimony) logo is seen displayed on a smartphone screen.

Why This Small-Cap Penny Stock Is Rallying Today – Traders Expect Stock Price To Double

United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility.

<ul class="summary-bullets"><li>BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares.</li><li>Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal.</li><li>Company’s CFO Sean Ricker said earlier this month that the company was “97% of the way” to reaching the required votes.</li></ul>Shares of Bigbear.ai were under investors’ radar and the top trending stock on Stocktwits ahead of its shareholder vote deadline on the company's proposal to increase its authorized common stock.&nbsp;The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares. The shareholder vote deadline is till 11:59 PM ET on Wednesday. The approval will be decided at a reconvened special meeting on Thursday.&nbsp;BigBear.ai’s proposal to increase the authorized shares had failed to secure enough votes last month.&nbsp;<h2 class="st-heading-2">Why It Matters</h2>Authorized shares put a legal maximum limit of shares a company can issue. Increasing the limit of authorized shares helps a company make finance acquisitions and compensate its employees with stock.&nbsp;BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares and has urged shareholders to vote in favour of the amendment. He said that approval “would not result in the immediate issuance of new shares.”Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal, he said in a letter to shareholders. “Having access to available authorized shares has allowed us over the years to make important acquisitions, fund product development and strengthen our balance sheet,” he added.&nbsp;The letter also said that additional shares would be available in the future to help fuel the company's growth as it looks to expand its AI capabilities, invest in its technology and Research and Development, invest in attracting and retaining top talent, and evaluating and acting on opportunistic financing and strategic initiatives.&nbsp;Company’s CFO Sean Ricker <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://bigbear.ai/blog/attention-shareholders-your-proxy-vote-questions-answered/?utm_source=ts2.tech">said</a> earlier this month that the company was “97% of the way” to reaching the required votes and added that “very few shares remain” under the current authorization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BBAI trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares of the company have fallen 2.4% year-to-date.&nbsp; &nbsp;

The BigBear.ai Holdings Inc logo appears on a smartphone screen and as a background on a laptop screen in this photo illustration in Athens, Greece.

BigBear.ai Shares Tumble 8% Ahead Of Crucial Shareholder Vote Deadline On Increasing Authorized Shares

The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares.

Vanguard Group, Inc. - Vanguard Russell 2000 Growth Index ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $CRWD earnings on Tuesday?

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF